For patients with higher-grade or progressive IDH -mutant glioma, how do you individualize choice between radiotherapy (RT) ...
Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...
A 62-year-old woman with stage IIIA lung cancer faces complex diagnostic and treatment decisions, highlighting the importance ...
Experts discuss the underutilization of biomarker testing in metastatic lung cancer, emphasizing the need for improved ...
Experts explore a virtual collaborative care model to enhance mental health support for breast cancer patients, aiming to ...
CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...
A subgroup analysis of the phase 3 FOCUS study (NCT02678572) shows that the Melphalan/Hepatic Delivery System (HDS; HEPZATO ...
CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...
A new drug application (NDA) has been submitted to the FDA seeking approval of rusfertide, an investigational hepcidin ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
Laura Huppert, MD, discusses efficacy and safety outcomes from the phase 3 ASCENT-04 trial, which compared the combination of ...
The FDA approval of denileukin diftitox (Lymphir) marked a significant shift in this paradigm. As a first-in-class immunotoxin, it employs a dual-action mechanism: directly targeting interleukin-2 (IL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback